- Home
- MIRM vs SAH Comparison
MIRM vs SAH Comparison
Compare MIRM & SAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- SAH
- Stock Information
- Founded
- MIRM 2018
- SAH 1997
- Country
- MIRM United States
- SAH United States
- Employees
- MIRM N/A
- SAH N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- SAH Other Specialty Stores
- Sector
- MIRM Health Care
- SAH Consumer Discretionary
- Exchange
- MIRM Nasdaq
- SAH Nasdaq
- Market Cap
- MIRM 2.5B
- SAH 2.5B
- IPO Year
- MIRM 2019
- SAH 1997
- Fundamental
- Price
- MIRM $52.45
- SAH $68.60
- Analyst Decision
- MIRM Strong Buy
- SAH Buy
- Analyst Count
- MIRM 11
- SAH 6
- Target Price
- MIRM $57.00
- SAH $72.67
- AVG Volume (30 Days)
- MIRM 504.4K
- SAH 206.1K
- Earning Date
- MIRM 02-26-2025
- SAH 02-12-2025
- Dividend Yield
- MIRM N/A
- SAH 2.03%
- EPS Growth
- MIRM N/A
- SAH 24.35
- EPS
- MIRM N/A
- SAH 6.18
- Revenue
- MIRM $307,028,000.00
- SAH $14,224,300,000.00
- Revenue This Year
- MIRM $83.04
- SAH $2.61
- Revenue Next Year
- MIRM $27.22
- SAH $5.78
- P/E Ratio
- MIRM N/A
- SAH $11.10
- Revenue Growth
- MIRM 112.14
- SAH N/A
- 52 Week Low
- MIRM $23.14
- SAH $47.82
- 52 Week High
- MIRM $54.23
- SAH $76.78
- Technical
- Relative Strength Index (RSI)
- MIRM 64.07
- SAH 41.73
- Support Level
- MIRM $51.02
- SAH $70.82
- Resistance Level
- MIRM $53.76
- SAH $76.78
- Average True Range (ATR)
- MIRM 2.04
- SAH 2.27
- MACD
- MIRM 0.03
- SAH -0.71
- Stochastic Oscillator
- MIRM 73.31
- SAH 4.66
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About SAH Sonic Automotive Inc.
Sonic Automotive is one of the largest auto dealership groups in the United States. The company has 108 franchised stores in 18 states, primarily in metropolitan areas in California, Texas, and the Southeast, plus 25 EchoPark used-vehicle stores, 16 collision centers, and 13 powersports locations. The franchise stores derive revenue from new and used vehicles plus parts and collision repair, finance, insurance, and wholesale auctions. Luxury and import dealerships make up about 86% of franchise new-vehicle revenue, while Honda, BMW, Mercedes, and Toyota constitute about 58% of new-vehicle revenue. BMW is the largest brand at about 25%. 2023's revenue was $14.4 billion, with EchoPark's portion totaling $2.4 billion. Sonic bought RFJ Auto in December 2021, which added $3.2 billion in sales.